Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Circulation

• Publication date

  2014-02-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.113.004450PMID 24344086
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OF THE UNITED STATES

  2015cited by this paper
• Oral apixaban for the treatment of acute venous thromboembolism.

  2013cited by this paper
• Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

  2013cited by this paper
• [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

  2013cited by this paper
• Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

  2013cited by this paper
• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011cited by this paper
• Emergency hospitalizations for adverse drug events in older Americans.

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Pre‐eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission

  2011cited by this paper
• Apixaban with antiplatelet therapy after acute coronary syndrome.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Newly identified events in the RE-LY trial.

  2010cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

  2010cited by this paper
• Drug and dietary interactions of the new and emerging oral anticoagulants

  2010cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

  2009cited by this paper
• Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Idraparinux versus standard therapy for venous thromboembolic disease.

  2007cited by this paper
• Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

  2006cited by this paper
• Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular- Weight Heparin for Acute Treatment of Venous Thromboembolism

  2006cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

  2005cited by this paper
• Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial

  2005cited by this paper
• Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.

  2005cited by this paper
• Fondaparinux or enoxaparin for initial treatment of symptomatic deep venous thrombosis: Randomized trial

  2004cited by this paper
• Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis

  2004cited by this paper
• Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.

  2003cited by this paper
• Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

  2003cited by this paper
• A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism

  1996cited by this paper
• Cost-effectiveness analyses.

  1995cited by this paper
• A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

  1995cited by this paper
• Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis

  1995cited by this paper

• Safety and Efficacy of Direct Oral Anticoagulants Versus Standard Therapy for Venous Thromboembolism in Cancer Patients: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

  2026cites this paper
• Contemporary Challenges in Venous Thromboembolism: Evolving Populations and Implications for Management and Risk Stratification.

  2026cites this paper
• Antithrombotic therapy for cancer-associated venous thromboembolism.

  2026cites this paper
• Safety and optimal use of direct oral anticoagulant therapy.

  2025cites this paper
• Venous Thromboembolism Outcomes by Geographic Region and Self-Reported Race: Insights from the RIETE Registry

  2025cites this paper
• Comparative Risk of Nonvertebral Fractures Associated with Oral Anticoagulants in Patients with Venous Thromboembolism.

  2025cites this paper
• No shots needed: direct oral anticoagulants in cancer-associated thrombosis-10-year follow-up.

  2025cites this paper
• Medical Management of Acute Venous Thromboembolism

  2025cites this paper
• Oral anticoagulation therapy in the setting of liver disease

  2025cites this paper
• Economic Evaluation of Direct Oral Anticoagulants Versus Low-Molecular Weight Heparin for Cancer-Associated Thrombosis in a Thai University-Affiliated Hospital

  2025cites this paper
• Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE.

  2025cites this paper
• Controversies and challenges of anticoagulation therapy in obesity

  2025cites this paper
• Fragile Flow: Deep Vein Thrombosis and Interventions in an Aging Vascular Landscape

  2025cites this paper
• Scalable confounding adjustment in real-world evidence: benchmarking data-adaptive and investigator-specified strategies in a large-scale trial emulation study.

  2025cites this paper
• [Diagnosis and treatment of acute pulmonary embolism].

  2025cites this paper
• Intermediate-Risk Pulmonary Embolism: Patients’ Stratification, Prognosis, and Therapeutic Options—Time to Pay Attention to the Middle Child

  2025cites this paper
• Oral Anticoagulants in Women: What's the Difference? A Narrative Review

  2025cites this paper
• Treatment of acute pulmonary embolism: A comparison of international guideline recommendations.

  2025cites this paper
• Anticoagulants: From chance discovery to structure-based design.

  2025cites this paper
• Risk-factors and multimorbidity in oral anticoagulant-related intracerebral haemorrhage: a comparison of patients in pivotal trials and real life.

  2025cites this paper
• [Diagnosis and treatment of acute pulmonary embolism].

  2025cites this paper
• Quelle place reste-t-il pour les antivitamines K ?

  2025cites this paper
• Bleeding Risk and Performance of Bleeding Risk Assessment Models in Patients with Venous Thromboembolism on Anticoagulation: Results from the prospective BACH-VTE Study.

  2025cites this paper
• Pericardial Effusion Associated With Direct Oral Anticoagulant Use in a Single Center Experience

  2025cites this paper
• Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants.

  2024cites this paper
• Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors

  2024cites this paper
• Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular

  2024cites this paper
• Forced randomization: the what, why, and how

  2024cites this paper
• Discovery of Heparin Mimetic, Potent, and Selective Inhibitors of Human Clotting Factor XIIIa

  2024cites this paper
• Diretriz de Avaliação Cardiovascular Perioperatória da Sociedade Brasileira de Cardiologia – 2024

  2024cites this paper
• Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review

  2024cites this paper
• Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery

  2024cites this paper
• Anticoagulation in the Management of Acute Pulmonary Embolism—A Review

  2024cites this paper
• Multidisciplinary Expert Guidance for the Management of Severe Bleeding on Oral Anticoagulation: An Algorithm for Practicing Clinicians

  2024cites this paper
• Efficacy and Safety of Direct Oral Anticoagulants for Acute Treatment of Venous Thromboembolism in Older Adults: A Network Meta-Analysis of Randomised Controlled Trials

  2024cites this paper
• Case Report: Deep vein thrombosis and pulmonary embolism secondary to urinary retention in a neurogenic bladder

  2024cites this paper
• Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology – 2024

  2024cites this paper
• Anticoagulants : utilisation pratique

  2024cites this paper
• Ultra-Early Hemostatic Therapy for Acute Intracerebral Hemorrhage: An Updated Review

  2024cites this paper
• Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe

  2024cites this paper
• Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

  2024cites this paper
• The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.

  2024cites this paper
• Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity

  2024cites this paper
• Equivalent thrombotic risk with Warfarin, Dabigatran, or Enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy

  2024cites this paper
• The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases

  2024cites this paper
• Artificial Intelligence Applied in Early Prediction of Lower Limb Fracture Complications

  2024cites this paper
• Bleeding Risk in Hemodialysis Patients.

  2024cites this paper
• New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants

  2024cites this paper
• Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade

  2024cites this paper
• Association of Different Anticoagulation Strategies With Outcomes in Patients Hospitalized With Acute Pulmonary Embolism

  2024influential citation
• Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma

  2024cites this paper
• Effect of direct oral anticoagulant therapy on pulmonary artery clot dissolution in intermediate high-risk pulmonary thromboembolism

  2024cites this paper
• Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients with Venous Thromboembolism using Real-World Data: A Systematic Review and Meta-Analysis

  2024cites this paper
• Anticoagulant Therapy in Patients Undergoing Acute Pulmonary Embolism Interventions.

  2024cites this paper
• Treatment of acute pulmonary embolism after catheter-directed thrombolysis with dabigatran vs warfarin: Results of a multicenter randomized RE-SPIRE trial

  2024influential citation
• Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Platelet–Neutrophil Crosstalk in Thrombosis

  2023cites this paper
• A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry

  2023cites this paper
• Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis

  2023cites this paper
• To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice

  2023cites this paper
• Thrombose veineuse profonde des membres inférieurs

  2023cites this paper
• Clinical Studies with Anticoagulants that Have Changed Clinical Practice

  2023cites this paper
• Direct Oral Anticoagulants for Pulmonary Embolism

  2023cites this paper
• Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications

  2023cites this paper
• Contemporary anticoagulant treatment strategies in patients with acute pulmonary embolism at different risk for death.

  2023cites this paper
• Thrombosis and Aging: Fibrin Clot Properties and Oxidative Stress

  2023cites this paper
• Global Research Hotspots in Venous Thromboembolism Anticoagulation: A Knowledge-Map Analysis from 2012 to 2021

  2023cites this paper
• Anticoagulation in Chronic Kidney Disease: current status and future perspectives.

  2023cites this paper
• Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism

  2023influential citation
• Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry

  2023cites this paper
• Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension.

  2023cites this paper
• Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents

  2023cites this paper
• Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials

  2023influential citation
• OPTIMIZATION OF VITAMIN K ANTAGONISTS LABORATORY MONITORING AND TECARFARIN : TWO FUTURE SOLUTIONS FOR ORAL ANTICOAGULANT TREATMENT ?

  2023cites this paper
• Thrombosis and Haemostasis Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study

  2023cites this paper
• A Systematic Review and Bayesian Network Meta-Analysis on the Effect of Different Anticoagulants on the Prophylaxis of Post-Thrombotic Syndrome after Deep Venous Thrombosis

  2023cites this paper
• Venous thromboembolism mortality and trends in older US adults, 2011–2019

  2023cites this paper
• DOACs use in extreme body-weighted patients: results from the prospective START-register

  2023cites this paper
• Anticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review

  2023cites this paper
• OPTIMIZATION OF VITAMIN K ANTAGONISTS LABORATORY MONITORING AND TECARFARIN : TWO FUTURE SOLUTIONS FOR ORAL ANTICOAGULANT TREATMENT ?

  2023cites this paper
• Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism.

  2023cites this paper
• Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.

  2023cites this paper
• Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials

  2023cites this paper
• MAJOR ACUTE CARDIOVASCULAR EVENTS AFTER VENOUS THROMBOEMBOLISM: A META-ANALYSIS OF RANDOMIZED TRIALS.

  2023cites this paper
• Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.

  2023cites this paper
• Hemostatic considerations for gender affirming care.

  2023cites this paper
• Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline

  2023cites this paper
• Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study

  2022cites this paper
• Direct Oral Anticoagulants vs Vitamin-K Antagonists in Thrombotic Antiphospholipid Syndrome: Meta-analysis of Randomized Controlled Trials.

  2022cites this paper
• Triazol-1-yl Benzamides Promote Anticoagulant Activity via Inhibition of Factor XIIa.

  2022cites this paper
• A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study

  2022cites this paper
• All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a protocol for a systematic review and meta-analysis

  2022cites this paper
• Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients

  2022cites this paper
• Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis

  2022cites this paper
• In Vivo Anticoagulant and Antithrombic Activity of Depolymerized Glycosaminoglycan from Apostichopus japonicus and Dynamic Effect–Exposure Relationship in Rat Plasma

  2022cites this paper
• Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known

  2022cites this paper
• Trends in post-discharge prophylactic anticoagulant use among stroke patients in the United States between 2006 and 2019.

  2022cites this paper
• Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multi-database cohort study.

  2022cites this paper
• Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis

  2022cites this paper
• Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia

  2022cites this paper